NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter of 2022 and provided a business update.
Acumen Pharmaceuticals reported its financial results for Q1 2022, highlighting progress in its INTERCEPT-AD Phase 1 clinical trial and a cash balance of $216.7 million expected to fund operations through 2025.
- Advanced INTERCEPT-AD, a Phase 1 clinical trial for ACU193 in early Alzheimer’s disease patients, with topline results expected in the first half of 2023.
- Published preclinical evidence in Frontiers in Neuroscience supporting ACU193's selective targeting of toxic soluble amyloid-beta oligomers.
- Maintained a strong cash position with $216.7 million in cash, cash equivalents, and marketable securities as of March 31, 2022, expected to provide cash runway through 2025.
- Increased research and development expenses due to ongoing clinical trial costs.
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$16K
Forward guidance
Acumen anticipates topline data from the INTERCEPT-AD trial in the first half of 2023 and plans to be ready to initiate a Phase 2/3 trial if INTERCEPT-AD results are positive. The company expects its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements through 2025 based on current plans.
Tailwinds
- Topline data from INTERCEPT-AD trial expected in the first half of 2023.
- Phase 2/3 clinical trial preparation activities progressing.
- Plans to initiate a Phase 2/3 trial if INTERCEPT-AD results are positive.
- Chronic toxicology and CMC activities are ongoing to support readiness.
- Cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements through 2025.
Headwinds
- Topline data from INTERCEPT-AD trial is subject to the rate of site activation and patient recruitment.
- Clinical trials are subject to risks and uncertainties.
- The impacts of the COVID-19 pandemic may amplify risks.
- The company is still in the clinical stage of development and has not yet commercialized any products.
- Future filings and reports by Acumen may describe additional risks concerning Acumen’s programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2022
+0.6%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.3% | -9.8% | — | |
| Q1 2026 | -3.5% | -11.7% | -7.8% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro